DIM-95031-006: A single arm, open-label Phase 3b study to describe the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagnosed with mIDH1 acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy (DIM-95031-006)

Principal Investigator

Connor Sweeney

Contact us

Email: Latephasehaematology@ouh.nhs.uk

IRAS number

1007001